Blog

The landscape of genomic medicine is shifting rapidly, necessitating a regulatory framework that is as dynamic as the technologies it oversees. In 2024, FDA released a guidance document discussing strategic considerations for developing cell and gene therapy products. A new guidance release last month serves as a specialized technical extension of the foundational January 2024 GE Guidance, focusing squarely on the analytical rigor required for NGS-based assessments. … Read more

When the clock is ticking for a patient who has exhausted every approved therapeutic intervention, the distinction between a “clinical trial” and “clinical survival” becomes life-defining. For the critically ill, the dual pillars of Expanded Access (EA) and Right to Try (RTT) represent more than just regulatory pathways; they are the final conduits of hope … Read more

Building on our previous discussion of the “Single-Trial Pivot,” we’ve seen the FDA move away from the rigid 1962 dual-study precedent toward a more flexible, evidence-based approach for precision therapies. But while that shift was initially signaled through journal articles and informal policy trends, the Agency has now codified a critical component of this evolution. With the release of the new … Read more

The landscape of medical device oversight is undergoing a seismic shift as the FDA pivots toward a more dynamic, data-driven inspection framework. For senior executives, staying ahead of these regulatory currents is not just a compliance requirement, it is a strategic imperative. The recent FDA town hall underscored a move toward high-velocity, risk-based methodologies designed to optimize oversight in … Read more

The landscape of modern pharmacology is shifting beneath our feet, moving from serendipitous discovery toward a regime of predictive, data-driven precision. For decades, the “undruggable” targets of the human proteome remained an impenetrable fortress, defying conventional high-throughput screening and traditional medicinal chemistry. However, a new dawn is breaking where artificial intelligence (AI) transcends its role … Read more

The life sciences industry is currently navigating a seismic shift as Generative AI transitions from a theoretical novelty to a core operational tool. We are witnessing the dawn of the “Automated Scientist,” capable of synthesizing vast datasets and drafting complex documents in a fraction of the time required by traditional methods. However, beneath the surface … Read more

In the rapidly evolving landscape of drug development, the static boundaries of frequentist statistics are finally being challenged by a more dynamic, iterative framework. For years, Bayesian approaches remained at the periphery of drug approvals, often relegated to early-phase dose-finding or exploratory sub-studies. A new FDA guidance changes the calculus, providing a formal roadmap for … Read more

The FDA Commissioner’s recent announcement streamlining the Investigational New Drug (IND) process is a breath of fresh air for an industry often suffocated by its own data. By proposing a reduction in the non-safety-related requirements for early-stage applications, the Agency is signaling a pivot toward common sense in clinical entry. For those of us in … Read more

For decades, the Limulus Amebocyte Lysate (LAL) test has served as the gold standard for detecting bacterial endotoxins, yet evolving manufacturing complexities demand a more nuanced regulatory approach. The FDA’s updated guidance on pyrogen and endotoxin testing marks a significant shift, bridging the gap between legacy methodologies and modern analytical capabilities. As product portfolios expand … Read more

Although 3D printing for drugs and biologics still has ways to go to become common, the FDA and EMA have been receptive to proposal for products using this technology. As 3D printing (3DP) moves from rapid prototyping to the mass customization of solid oral dosage forms, regulatory frameworks are rapidly evolving to catch up with … Read more